{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:14:51Z","timestamp":1788012891487,"version":"build-2784847793"},"reference-count":56,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n Andaluza de Reumatolog\u00eda"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis\u2013associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2\u201342.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03\u20133.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70\u20130.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72\u20130.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.<\/jats:p>","DOI":"10.3390\/biomedicines10071480","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:31:06Z","timestamp":1655933466000},"page":"1480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis\u2013Associated Interstitial Lung Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Natalia","family":"Mena-V\u00e1zquez","sequence":"first","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rojas-Gimenez","sequence":"additional","affiliation":[{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 Cordova, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba, 14004 Cordova, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Fuego-Varela","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario de Jerez, 11407 Cadiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimara","family":"Garc\u00eda-Studer","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nair","family":"Perez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Complejo Hospitalario Universitario de Vigo, 36214 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Mar\u00eda","family":"Romero-Barco","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Cl\u00ednico Universitario Virgen de la Victoria, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Godoy-Navarrete","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario de Ja\u00e9n, 23007 Jaen, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Manrique-Arija","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"},{"name":"Departamento de Medicina, Universidad de M\u00e1laga, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Gand\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario de Jerez, 11407 Cadiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerusalem","family":"Calvo-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 Cordova, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba, 14004 Cordova, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Morales-Garrido","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario Cl\u00ednico San Cecilio, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Mouri\u00f1o-Rodriguez","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Complejo Hospitalario Universitario de Vigo, 36214 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Castro-P\u00e9rez","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario de Getafe, 28901 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-3224","authenticated-orcid":false,"given":"Isabel","family":"A\u00f1\u00f3n-O\u00f1ate","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario de Ja\u00e9n, 23007 Jaen, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Espildora","sequence":"additional","affiliation":[{"name":"UGC de Neumolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Aguilar-Hurtado","sequence":"additional","affiliation":[{"name":"UGC de Radiodiagn\u00f3stico, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Hidalgo Conde","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Arnedo D\u00edez de los R\u00edos","sequence":"additional","affiliation":[{"name":"Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Cabrera C\u00e9sar","sequence":"additional","affiliation":[{"name":"UGC Neumolog\u00eda, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Redondo-Rodriguez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Velloso-Feijoo","sequence":"additional","affiliation":[{"name":"UGC de Reumatolog\u00eda, Hospital Universitario Virgen de Valme, 41014 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2962-9844","authenticated-orcid":false,"given":"Antonio","family":"Fern\u00e1ndez-Nebro","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29010 Malaga, Spain"},{"name":"UGC de Reumatolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29009 Malaga, Spain"},{"name":"Departamento de Medicina, Universidad de M\u00e1laga, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40265-014-0190-z","article-title":"Interstitial lung disease in patients with rheumatoid arthritis: Spontaneous and drug induced","volume":"74","author":"Hallowell","year":"2014","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00296-017-3781-7","article-title":"Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis","volume":"37","author":"Kim","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-004-0472-y","article-title":"Pulmonary involvement in rheumatoid arthritis","volume":"25","author":"Bilgici","year":"2005","journal-title":"Rheumatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10067-018-4382-x","article-title":"Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: Single center study with a large sample of Chinese population","volume":"38","author":"Fu","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","article-title":"Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: A retrospective case control study","volume":"3","author":"Hozumi","year":"2013","journal-title":"BMJ Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ebiom.2018.01.038","article-title":"Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease","volume":"28","author":"Jacob","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","article-title":"Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nurmi, H.M., Purokivi, M.K., K\u00e4rkk\u00e4inen, M.S., Kettunen, H.-P., Selander, T.A., and Kaarteenaho, R.L. (2016). Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0269-2"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Methotrexate and the severity of lung disease are associated to prognosis","volume":"36","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/09031936.00019210","article-title":"Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome","volume":"37","author":"Tsuchiya","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3904\/kjim.2016.349","article-title":"Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Yang","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_15","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Krause","year":"2017","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","article-title":"Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug","volume":"168","author":"Saketkoo","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Barnes, H., Holland, A.E., Westall, G.P., Goh, N.S., and Glaspole, I.N. (2018). Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev., 1.","DOI":"10.1002\/14651858.CD010908.pub2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Luburich","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_21","first-page":"133","article-title":"Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis","volume":"40","author":"Espildora","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_22","first-page":"504","article-title":"Systematic Review of the Impact of Drugs on Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis","volume":"17","author":"Cubero","year":"2020","journal-title":"Reumatol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","article-title":"Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: A nationwide population-based study","volume":"60","author":"Ibfelt","year":"2020","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kiely, P., Busby, A.D., Nikiphorou, E., Sullivan, K., Walsh, D.A., Creamer, P., Dixey, J., and Young, A. (2019). Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open, 9.","DOI":"10.1136\/bmjopen-2018-028466"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Kabia","year":"2017","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Loricera","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: National multicenter study of 263 patients","volume":"59","year":"2020","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mena-V\u00e1zquez, N., Rojas-Gimenez, M., Romero-Barco, C.M., Manrique-Arija, S., Francisco, E., Aguilar-Hurtado, M.C., A\u00f1\u00f3n-O\u00f1ate, I., P\u00e9rez-Albaladejo, L., Ortega-Castro, R., and Godoy-Navarrete, F.J. (2021). Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040874"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/14397595.2018.1442170","article-title":"Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease","volume":"29","author":"Ito","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics\u2014A large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: A simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration"},{"key":"ref_35","first-page":"103","article-title":"Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia","volume":"30","author":"Song","year":"2013","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1800869","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","first-page":"216","article-title":"The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia","volume":"33","author":"Lee","year":"2016","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3109\/s10165-009-0187-8","article-title":"Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population","volume":"19","author":"Iwamoto","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/acr.20620","article-title":"Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)","volume":"63","author":"Maska","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_41","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2022, February 08). Informaci\u00f3n para las Notificaciones de Sospechas de Reacciones Adversas a Medicamentos por Parte de Profesionales Sanitarios, Available online: https:\/\/www.aemps.gob.es\/vigilancia\/medicamentosUsoHumano\/SEFVH\/NRA-SEFV-H\/notificaSospechas-RAM-profSanitarios.htm#NSRAPS."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/RHU.0000000000000084","article-title":"Abatacept therapy in rheumatoid arthritis with interstitial lung disease","volume":"20","year":"2014","journal-title":"J. Clin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Respir. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience","volume":"50","author":"Elhai","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: Short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cassone, G., Manfredi, A., Atzeni, F., Venerito, V., Vacchi, C., Picerno, V., Furini, F., Erre, G.L., Tomietto, P., and Fedele, A.L. (2020). Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010277"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2169\/internalmedicine.2226-18","article-title":"Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis","volume":"58","author":"Kurata","year":"2019","journal-title":"Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10067-015-3025-8","article-title":"Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Restrepo","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.yexmp.2011.09.010","article-title":"The effect of CTLA-4Ig, a CD28\/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis","volume":"91","author":"Arreola","year":"2011","journal-title":"Exp. Mol. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Juge, P.A., Lee, J.S., Lau, J., Kawano-Dourado, L., Rojas Serrano, J., Sebastiani, M., Koduri, G., Matteson, E., Bonfiglioli, K., and Sawamura, M. (2021). Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur. Respir. J., 57.","DOI":"10.1183\/13993003.00337-2020"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/diagnostics11101794","article-title":"Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study","volume":"11","author":"Espildora","year":"2021","journal-title":"Diagnostics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","article-title":"Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"22","author":"Qiu","year":"2021","journal-title":"Respir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review","volume":"20","author":"Blanco","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_56","first-page":"Cd008794","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:52Z","timestamp":1760139472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071480"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071480","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}